Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134682) titled 'Clinical study on BCMA-targeted T-cell engaging antibody therapy for immune thrombotic thrombocytopenic purpura resistant to rituximab and/or daratumumab' on Oct. 19.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: THE FIRST AFFILIATED HOSPITAL OF USTC ANHUI PROVINCAL HOSPITAL

Condition: Immune thrombotic thrombocytopenic purpura (iTTP)

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-10-19

Target Sample Size: experimental group:10;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=348288

Discl...